{
    "clinical_study": {
        "@rank": "100886", 
        "arm_group": {
            "arm_group_label": "Arm A: Ipilimumab", 
            "arm_group_type": "Experimental", 
            "description": "Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese\n      subjects with advanced melanoma"
        }, 
        "brief_title": "Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed diagnosis of malignant melanoma\n\n          -  Previously-treated or untreated unresectable Stage III or Stage IV melanoma\n\n          -  Measurable/evaluable disease per modified World Health Organization (mWHO) criteria,\n             within 28 days of first dose of study drug\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n        Exclusion Criteria:\n\n          -  Active brain metastases\n\n          -  Primary ocular or mucosal melanoma\n\n          -  History of or current active autoimmune disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990859", 
            "org_study_id": "CA184-396"
        }, 
        "intervention": {
            "arm_group_label": "Arm A: Ipilimumab", 
            "intervention_name": "Ipilimumab", 
            "intervention_type": "Biological", 
            "other_name": "BMS-734016"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "8128582"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto-shi", 
                        "country": "Japan", 
                        "state": "Kumamoto", 
                        "zip": "8608556"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsumoto-shi", 
                        "country": "Japan", 
                        "state": "Nagano", 
                        "zip": "3908621"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sunto-gun", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "4118777"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "1040045"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-shi", 
                        "country": "Japan", 
                        "state": "Yamanashi", 
                        "zip": "4093898"
                    }, 
                    "name": "Local Institution"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In addition, abnormal vital signs and physical examination findings are also included", 
            "measure": "Safety of Ipilimumab monotherapy based on serious and non-serious adverse events, laboratory evaluations, dose exposure and modifications", 
            "safety_issue": "Yes", 
            "time_frame": "At 12 weeks after first treatment of last subject"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990859"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Best Overall Response Rate, defined as the total number of subjects whose Best Overall Response is Complete Response (CR) or Partial Response (PR) divided by the total number of treated subjects.", 
            "measure": "Best overall response rate (BORR)", 
            "safety_issue": "No", 
            "time_frame": "At Screening (Within 28 days of first dose), weeks 12, 18, and 24 and every 12 weeks thereafter for at least 1 year after last subject's first treatment (Approximately 15 months)"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}